Overview of the CAR T-Cell Therapy Process: Apheresis, Manufacturing, Potential Bridging Therapies, Lymphodepletion, and Infusion
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy’s mechanism of action and treatment workflow requires extensive institutional coordination, from patient selection through bridging therapy and infusion, with varied approaches to managing patients during the manufacturing period across different centers.
EP: 1.Highlighted Data Review of CAR-T in Early R/R MM
EP: 2.Expert Insights: Distinguishing between CARTITUDE-4 vs. KarMMa-3 Trials
EP: 3.CAR-T in R/R MM: Patient Selection & Treatment Sequencing
EP: 4.CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel
EP: 5.MSKCC Insights: CAR T Referral Process
EP: 6.Overview of the CAR T-Cell Therapy Process: Apheresis, Manufacturing, Potential Bridging Therapies, Lymphodepletion, and Infusion
EP: 7.Collaboration With Community Colleagues: Comanagement and Transitions of Care
EP: 8.CAR T Referral Process: Challenges Seen and How They Can Be Addressed
EP: 9.MSKCC Experiences: Successful CAR T Collaborations With Community and International Providers
EP: 10.CAR-T Clinical Trials: Potentially Moving CAR T Into Earlier Lines of MM Treatment
EP: 11.Applying Evidence to Clinical Practice: 63-Year-Old Patient With R/R MM Post Dara-VRd Induction Scenario
EP: 12.CAR T in R/R MM: Key Takeaways and Pearls
Video content above is prompted by the following:
- Could you explain how CAR T-cell therapy works and describe the treatment process?
- Do you consider CAR T therapy a complex process at your institution, or have you been able to streamline the logistics and integration into clinical workflows?
- Dr Usmani to ask Dr Mailankody: Can you explain your institution’s approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion?
- Do you send patients back to community center or does it happen in-house?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
